Home・Stock List・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Closed

0.94

Buy Sell

Overview

Share price change

24h

Current

Min

0.94

Max

0.97

Key metrics
By Trading Economics
Income	418K -5.5M
EPS	-0.18
Profit margin	-6,600
Employees	25
EBITDA	906K -5.3M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+506.06% upside

Dividends
By Acuity
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-5.3M 32M
Previous open	0.94
Previous close	0.94

Actinium Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 Jun 2026, 23:51 UTC

"Bitcoin rises as Ethereum falls amid pivotal AI earnings reports, while U.S. credit rating remains stable and China's industrial profits soar."

27 Jun 2026, 23:51 UTC

China's industrial profits rise 18.8% amid AI investments; U.S. credit rating affirmed at AA+ as markets brace for modest growth and pivotal Meta earnings report.

27 Jun 2026, 23:51 UTC

Cryptocurrency market shows mixed signals as investors brace for key AI earnings reports and upcoming economic indicators amid cautious U.S. growth outlook.

27 Jun 2026, 23:51 UTC

Mixed cryptocurrency performance reflects cautious investor sentiment ahead of key economic indicators and AI earnings reports, while U.S. credit rating remains stable amid inflation concerns.

27 Jun 2026, 23:51 UTC

Bitcoin is trading higher since Friday's close, remaining flat during the current session. The price fluctuated within a routine range today.

27 Jun 2026, 23:42 UTC

U.S. Labor Force Participation Rate Release on July 2, 2026: Market Cautious Amid Declining Employee Confidence and Legislative Changes Impacting Employment Dynamics.

27 Jun 2026, 23:42 UTC

Market Awaits BoC Governor Macklem's Speech on Interest Rate Policy Amid Economic Uncertainties

27 Jun 2026, 23:42 UTC

Market Eyes BoE Governor Bailey's July Speech for Insights on UK Interest Rates Amid Global Monetary Policy Shifts.

27 Jun 2026, 23:42 UTC

Market Anticipates 0.3% Increase in U.S. Average Hourly Earnings Amid Wage Growth Concerns and Inflation Pressures Ahead of July Release.

27 Jun 2026, 23:42 UTC

U.S. Unemployment Rate Release on July 2, 2026 Expected at 4.3%, Amid Concerns Over Employee Confidence and Potential Minimum Wage Legislation Impacting Markets

27 Jun 2026, 23:42 UTC

Market Anticipates 114K Job Additions in Upcoming June NFP Report Amid Mixed Economic Sentiment and Inflation Concerns.

27 Jun 2026, 23:42 UTC

Market Awaits Key Average Hourly Earnings Data Amidst Rising Inflation Concerns and Potential Federal Reserve Rate Implications on July 2, 2026.

27 Jun 2026, 23:31 UTC

Mexican Consumer Confidence Expected to Remain Low Amid Economic Challenges Ahead of July 3 Data Release.

27 Jun 2026, 23:11 UTC

ADP Employment Change Report Forecasts 118,000 Job Increase Amid Cautious Optimism in Labor Market Ahead of July Release.

27 Jun 2026, 23:11 UTC

Correlated Moves

S&P 500 Index declines in after-market trading, reflecting cautious sentiment ahead of upcoming earnings reports from AI-linked companies like Meta.

27 Jun 2026, 23:11 UTC

Correlated Moves

The Russell 2000 Index is lower in after-market trading, reflecting broader market sentiment amid upcoming earnings reports from AI-linked companies.

27 Jun 2026, 23:11 UTC

Correlated Moves

The Dow Jones Index is lower in after-market hours, reflecting unusual trading activity and broader declines seen in the Russell 2000 Index.

27 Jun 2026, 23:11 UTC

The FTSE 100 Index is lower in after-market hours, reflecting a dip since Friday's close. Anticipation of corporate earnings reports may influence market sentiment.

27 Jun 2026, 23:11 UTC

Correlated Moves

The Nasdaq 100 Index is lower during after-market hours, continuing a downward trend since Friday's close amid broader market weakness and upcoming earnings anticipation.

27 Jun 2026, 23:02 UTC

Canada's May GDP report set for June 30, with a projected growth of 0.4% amid mixed stock performance and trade uncertainties.

27 Jun 2026, 22:32 UTC

Germany's June 30 inflation rate forecasted to rise by 0.1%, raising concerns over persistent inflation and potential ECB monetary policy shifts amid global economic pressures.

27 Jun 2026, 22:32 UTC

Germany's June 2026 Inflation Rate Release Expected at 2.5% Amid Rising Global Price Pressures and Cautious Market Sentiment

27 Jun 2026, 22:32 UTC

Japan's Tankan Large Manufacturers Index set for June 30, with cautious market sentiment amid stock declines and mixed economic signals.

27 Jun 2026, 22:32 UTC

South Africa's Upcoming Balance of Trade Data Expected to Show Significant Shift Amid Rising Imports and Mixed Export Performance

27 Jun 2026, 22:21 UTC

Brazil's Central Bank to Provide Key Insights on Interest Rate Outlook Amid Rising Global Pressures in June 29 Readout.

27 Jun 2026, 22:11 UTC

Japan's Industrial Production Expected to Rise 1.1% in May Amid Mixed Market Sentiment and Economic Concerns

27 Jun 2026, 22:02 UTC

South Korea's June 2026 Inflation Rate Release Sparks Market Caution Amid Rising Price Pressures and Regional Economic Concerns.

27 Jun 2026, 21:51 UTC

Japan's Retail Sales YoY data for May set to release on June 28, with a projected growth of 3.2% amid mixed market sentiment and inflation concerns.

27 Jun 2026, 21:51 UTC

Japan's Unemployment Rate Expected to Stabilize at 2.5% Amid Mixed Economic Sentiment and Market Volatility

27 Jun 2026, 21:41 UTC

Cautious Sentiment Surrounds Upcoming Ai Group Industry Index Release Amid Ongoing Economic Challenges in Australia

Peer Comparison

Price change

Actinium Pharmaceuticals Inc Forecast

Price Target

By TipRanks

506.06% upside

12 Months Forecast

Average 6 USD 506.06%

High 9 USD

Low 4 USD

Based on 3 Wall Street analysts offering 12 month price targets forActinium Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Actinium Pharmaceuticals Inc - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.